With the well-documented promotive role of estrogen in breast cancer in mind, investigators aimed to compare breast cancer risk among postmenopausal women with long-term estrogen use vs those who did not...
Researchers prospectively evaluated bone data of more than 200 breast cancer survivors and more than 500 cancer-free women to compare osteopenia and osteoporosis incidence.
Previous research has indicated that hyperlipidemia may be a risk factor for cancer, although the effects of the condition, and of cholesterol-lowering drugs on cancer risk remain uncertain.
The US Food and Drug Administration has expanded the approval of Faslodex, a hormonal therapy for the treatment of breast cancer first approved in 2002.
After a review of existing data, the Endocrine Society has released several recommendations and statements regarding the treatment of symptoms associated with estrogen depletion following breast cancer. ...
In a recent study, researchers tested the safety and efficacy of a treatment combination for women with advanced breast cancer who experienced disease progression while receiving endocrine therapy. To see...
The US Food and Drug Administration recently approved a new treatment option for patients with early stage HER2-overexpressed/amplified breast cancer. For recommended dosage and common adverse events, read...
In a recent trial, researchers may have found a safe and effective alternative treatment for certain breast cancer patients who are not suited for systemic chemotherapy. For results of the trial, including...
After the results from a phase III randomized trial demonstrated its efficacy, the American Society of Clinical Oncology updated its guidelines to include a new genomic test. For information regarding...
The American College of Obstetricians and Gynecologists has recently released updated clinical guidelines on breast cancer screening in women facing average risk.
